• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

膀胱癌：现状与未来。

Bladder cancer: Present and future.

机构信息

Servicio de Urología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España.

Servicio de Urología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España.

出版信息

Med Clin (Barc). 2017 Nov 22;149(10):449-455. doi: 10.1016/j.medcli.2017.06.009. Epub 2017 Jul 21.

DOI:10.1016/j.medcli.2017.06.009
PMID:28736063
Abstract

Bladder cancer has a high incidence and involves high associated morbidity and mortality. Since its initial clinical suspicion, early diagnostic confirmation and multimodal treatment involve different medical specialties. For this reason, we consider it important to spread the current consensus for its management. Recent advances in immunology and Chemotherapy make it necessary to expose and reflect on future perspectives.

摘要

膀胱癌发病率高，涉及的相关发病率和死亡率也很高。从最初的临床怀疑到早期诊断确认再到多模式治疗，涉及不同的医学专业。出于这个原因，我们认为传播目前的管理共识很重要。免疫治疗和化学治疗的最新进展使得有必要揭示和思考未来的前景。

相似文献

1
Bladder cancer: Present and future.膀胱癌：现状与未来。
Med Clin (Barc). 2017 Nov 22;149(10):449-455. doi: 10.1016/j.medcli.2017.06.009. Epub 2017 Jul 21.
2
Treatment of non muscle invasive bladder tumor related to the problem of bacillus Calmette-Guerin availability. Consensus of a Spanish expert's panel. Spanish Association of Urology.与卡介苗供应问题相关的非肌层浸润性膀胱肿瘤的治疗。西班牙专家小组共识。西班牙泌尿外科学会
Actas Urol Esp. 2013 Jul-Aug;37(7):387-94. doi: 10.1016/j.acuro.2013.04.002. Epub 2013 Jun 14.
3
UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria.尿液中的泛素结合酶E2C无细胞RNA能够区分膀胱癌和血尿。
Oncotarget. 2016 Sep 6;7(36):58193-58202. doi: 10.18632/oncotarget.11277.
4
Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.高危Ta、T1期膀胱癌诱导使用卡介苗后的复发模式及预后
J Urol. 2007 May;177(5):1727-31. doi: 10.1016/j.juro.2007.01.031.
5
Bladder cancer.膀胱癌
Curr Opin Oncol. 2006 May;18(3):277-83. doi: 10.1097/01.cco.0000219258.75961.1a.
6
Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy.卡介苗对膀胱尿路上皮癌T1G3的多种保守治疗方案的回顾性研究：维持治疗。
Actas Urol Esp. 2016 Jul-Aug;40(6):370-7. doi: 10.1016/j.acuro.2015.12.009. Epub 2016 Feb 24.
7
Diagnosis and staging of bladder cancer.膀胱癌的诊断与分期
Hematol Oncol Clin North Am. 2015 Apr;29(2):205-18, vii. doi: 10.1016/j.hoc.2014.10.013. Epub 2014 Nov 6.
8
Diagnosis and treatment of bladder cancer: how can we improve?膀胱癌的诊断与治疗：如何改善？
Postgrad Med. 2012 May;124(3):28-36. doi: 10.3810/pgm.2012.05.2545.
9
Bladder cancer.膀胱癌。
Curr Opin Oncol. 2010 May;22(3):242-9. doi: 10.1097/CCO.0b013e3283378c6b.
10
Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies.重组卡介苗在膀胱尿路上皮癌免疫治疗中的应用：当前策略
Expert Rev Anticancer Ther. 2015 Jan;15(1):85-93. doi: 10.1586/14737140.2015.961430. Epub 2014 Sep 18.

引用本文的文献

1
Identification and validation of a novel signature based on M2 macrophage co-expressed genes in bladder cancer.基于M2巨噬细胞共表达基因的膀胱癌新型标志物的鉴定与验证
Transl Cancer Res. 2025 Jul 30;14(7):4194-4207. doi: 10.21037/tcr-24-2013. Epub 2025 Jul 22.
2
Bladder cancer biomarker analysis and drugtarget prediction based on pyroptosis-related genes.基于焦亡相关基因的膀胱癌生物标志物分析及药物靶点预测
Discov Oncol. 2025 May 25;16(1):924. doi: 10.1007/s12672-025-02754-2.
3
Nanoparticle-mediated targeting of PGC-1α reveals critical metabolic pathways in bladder cancer metastasis.
纳米颗粒介导的PGC-1α靶向揭示了膀胱癌转移中的关键代谢途径。
Commun Biol. 2025 May 23;8(1):788. doi: 10.1038/s42003-025-08174-w.
4
Correlation between HMGB1 expression and drug resistance and prognosis in patients with bladder urothelial carcinoma.膀胱尿路上皮癌患者中HMGB1表达与耐药性及预后的相关性
Discov Oncol. 2025 May 8;16(1):695. doi: 10.1007/s12672-025-02466-7.
5
Estimated prediction of urinary tract neoplasms using the identify risk calculator in patients with haematuria.使用血尿患者风险识别计算器对尿路肿瘤进行估计预测。
Cent European J Urol. 2024;77(4):612-617. doi: 10.5173/ceju.2024.0113. Epub 2024 Dec 28.
6
Trends in tobacco smoking and bladder and lung-bronchial cancer rates among non-hispanic white Americans (2000-2016).2000年至2016年非西班牙裔美国白人的吸烟趋势以及膀胱癌和肺-支气管癌发病率
Arch Public Health. 2025 Apr 24;83(1):113. doi: 10.1186/s13690-025-01585-5.
7
COTI-2 suppresses the malignancy of bladder cancer by inducing apoptosis via the AMPK-mTOR signaling pathway.COTI-2通过AMPK-mTOR信号通路诱导细胞凋亡，从而抑制膀胱癌的恶性肿瘤生长。
Iran J Basic Med Sci. 2025;28(3):240-246. doi: 10.22038/ijbms.2024.80284.17378.
8
Combining a Risk Factor Score Designed From Electronic Health Records With a Digital Cytology Image Scoring System to Improve Bladder Cancer Detection: Proof-of-Concept Study.将基于电子健康记录设计的风险因素评分与数字细胞学图像评分系统相结合以改善膀胱癌检测：概念验证研究。
J Med Internet Res. 2025 Jan 22;27:e56946. doi: 10.2196/56946.
9
Identification and validation of the nicotine metabolism-related signature of bladder cancer by bioinformatics and machine learning.通过生物信息学和机器学习鉴定并验证膀胱癌尼古丁代谢相关特征
Front Immunol. 2024 Dec 17;15:1465638. doi: 10.3389/fimmu.2024.1465638. eCollection 2024.
10
Immunogenic cell death-related signature predicts prognosis and immunotherapy efficacy in bladder cancer.免疫原性细胞死亡相关特征预测膀胱癌的预后和免疫治疗疗效。
Transl Cancer Res. 2024 Nov 30;13(11):5801-5814. doi: 10.21037/tcr-24-533. Epub 2024 Nov 27.